Literature DB >> 20631693

Refilling and switching of antiepileptic drugs and seizure-related events.

J J Gagne1, J Avorn, W H Shrank, S Schneeweiss.   

Abstract

We sought to estimate the risk of seizure-related events associated with refilling prescriptions for antiepileptic drugs (AEDs) and to estimate the effect of switching between brand-name and generic drugs or between two generic versions of the same drug. We conducted a case-crossover study using health-care databases from British Columbia, Canada, among AED users who had an emergency room visit or hospitalization for seizure (index seizure-related event), defined using International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9) codes 345.xx (epilepsy and recurrent seizures) and 780.3x (convulsions), between 1997 and 2005. AED prescription refilling itself was associated with 2.3-fold elevated odds of seizure-related events when the refill occurred within 21 days before the index event (odds ratio (OR) 2.31; 95% confidence interval (CI) 1.56-3.44). The OR was 2.75 (95% CI 0.88-8.64) for refills that involved switching, yielding a refill-adjusted OR for switching of 1.19 (95% CI 0.35-3.99). Refilling the same AED prescription was associated with an elevated risk of seizure-related events whether or not the refill involved switching from a brand-name to a generic product.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20631693      PMCID: PMC2996138          DOI: 10.1038/clpt.2010.90

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  39 in total

1.  Chronobiology. Suggestions for integrating it into drug development.

Authors:  J G Harter; C C Peck
Journal:  Ann N Y Acad Sci       Date:  1991       Impact factor: 5.691

2.  What's the problem with generic antiepileptic drugs?: a call to action.

Authors:  Michel J Berg
Journal:  Neurology       Date:  2007-04-17       Impact factor: 9.910

3.  Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration.

Authors:  Barbara M Davit; Patrick E Nwakama; Gary J Buehler; Dale P Conner; Sam H Haidar; Devvrat T Patel; Yongsheng Yang; Lawrence X Yu; Janet Woodcock
Journal:  Ann Pharmacother       Date:  2009-09-23       Impact factor: 3.154

4.  The case-crossover design: a method for studying transient effects on the risk of acute events.

Authors:  M Maclure
Journal:  Am J Epidemiol       Date:  1991-01-15       Impact factor: 4.897

5.  Warfarin with fluoroquinolones, sulfonamides, or azole antifungals: interactions and the risk of hospitalization for gastrointestinal bleeding.

Authors:  H Schelleman; W B Bilker; C M Brensinger; X Han; S E Kimmel; S Hennessy
Journal:  Clin Pharmacol Ther       Date:  2008-08-06       Impact factor: 6.875

6.  Generic products of antiepileptic drugs (AEDs): is it an issue?

Authors:  Meir Bialer
Journal:  Epilepsia       Date:  2007-09-10       Impact factor: 5.864

7.  Effects of antiepileptic drug substitutions on epileptic events requiring acute care.

Authors:  Karen L Rascati; Kristin M Richards; Michael T Johnsrud; Teresa A Mann
Journal:  Pharmacotherapy       Date:  2009-07       Impact factor: 4.705

8.  The variability and quality of medication container labels.

Authors:  William H Shrank; Jessica Agnew-Blais; Niteesh K Choudhry; Michael S Wolf; Aaron S Kesselheim; Jerry Avorn; Paul Shekelle
Journal:  Arch Intern Med       Date:  2007-09-10

9.  Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes.

Authors:  Frederick Andermann; Mei Sheng Duh; Antoine Gosselin; Pierre Emmanuel Paradis
Journal:  Epilepsia       Date:  2007-03       Impact factor: 5.864

10.  Understanding patients' perspective in the use of generic antiepileptic drugs: compelling lessons for physicians to improve physician/patient communication.

Authors:  Kore Liow
Journal:  BMC Neurol       Date:  2009-03-17       Impact factor: 2.474

View more
  18 in total

1.  A comparison of the intrasubject variation in drug exposure between generic and brand-name drugs: a retrospective analysis of replicate design trials.

Authors:  Yang Yu; Steven Teerenstra; Cees Neef; David Burger; Marc Maliepaard
Journal:  Br J Clin Pharmacol       Date:  2016-01-15       Impact factor: 4.335

2.  Generic and therapeutic substitution: ethics meets health economics.

Authors:  Steven Simoens
Journal:  Int J Clin Pharm       Date:  2011-03-24

3.  Product-Specific Regulatory Pathways to Approve Generic Drugs: The Need for Follow-up Studies to Ensure Safety and Effectiveness.

Authors:  Aaron S Kesselheim; Joshua J Gagne
Journal:  Drug Saf       Date:  2015-10       Impact factor: 5.606

4.  Active Surveillance of Follow-on Biologics: A Prescription for Uptake.

Authors:  Ameet Sarpatwari; Joshua J Gagne; Nicole L Levidow; Aaron S Kesselheim
Journal:  Drug Saf       Date:  2017-02       Impact factor: 5.606

5.  Evaluation of Switching Patterns in FDA's Sentinel System: A New Tool to Assess Generic Drugs.

Authors:  Joshua J Gagne; Jennifer R Popovic; Michael Nguyen; Sukhminder K Sandhu; Patty Greene; Rima Izem; Wenlei Jiang; Zhong Wang; Yueqin Zhao; Andrew B Petrone; Anita K Wagner; Sarah K Dutcher
Journal:  Drug Saf       Date:  2018-12       Impact factor: 5.606

6.  Generic substitution of lamotrigine among medicaid patients with diverse indications: a cohort-crossover study.

Authors:  Daniel M Hartung; Luke Middleton; Leanne Svoboda; Jessina C McGregor
Journal:  CNS Drugs       Date:  2012-08-01       Impact factor: 5.749

Review 7.  Rational use of generic psychotropic drugs.

Authors:  Maren Carbon; Christoph U Correll
Journal:  CNS Drugs       Date:  2013-05       Impact factor: 5.749

8.  Generic products of antiepileptic drugs: a perspective on bioequivalence, bioavailability, and formulation switches using Monte Carlo simulations.

Authors:  Vangelis Karalis; Panos Macheras; Meir Bialer
Journal:  CNS Drugs       Date:  2014-01       Impact factor: 5.749

Review 9.  Generic drugs for hypertension: are they really equivalent?

Authors:  Rhonda M Cooper-DeHoff; William J Elliott
Journal:  Curr Hypertens Rep       Date:  2013-08       Impact factor: 5.369

10.  Factors associated with seizure recurrence in epilepsy patients treated with antiepileptic monotherapy: A retrospective observational cohort study using US administrative insurance claims.

Authors:  Natalia Shcherbakova; Karen Rascati; Carolyn Brown; Kenneth Lawson; Suzanne Novak; Kristin M Richards; Linda Yoder
Journal:  CNS Drugs       Date:  2014-11       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.